08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase (JNK); caspase recruitment domain family member 11 (CARD11)

Cancer INDICATION: B cell lymphoma Mouse and patient sample studies suggest JNK inhibitors could help treat a subtype of diffuse large B-cell lymphoma (DLBCL). Gain-of-function mutations in CARD11 are associated with poor outcomes in the active...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

NeoGenomics sales and marketing update

NeoGenomics launched new tests to detect mutations in the Bruton’s tyrosine kinase (BtK) and phospholipase C gamma 2 (phosphatidylinositol-specific; PLCG2) genes for predicting acquired resistance to BtK inhibitors and a lymphoma profiling test...